Spontaneous reporting of rare events associated with atypical antipsychotics using the FDA adverse event reporting system

被引：0
|
作者：
Emechebe, Nnadozie [1 ]
Mukhtar, Fahad [1 ,2 ]
Scheer, Darren [1 ,3 ]
Patel, Arshiya [4 ]
Wadhawan, Abhishek [2 ]
Schwartz, Skai [1 ]
Zgibor, Janice [1 ]
机构：
[1] Univ S Florida, Coll Publ Hlth, Dept Epidemiol & Biostat, Tampa, FL USA
[2] St Elizabeth Hosp, Psychiat Residency Training Program, Washington, DC USA
[3] Biotech Res Grp Corp, Tampa, FL USA
[4] Univ S Florida, Dept Global Hlth, Coll Publ Hlth, Tampa, FL USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2019年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
709
引用
收藏
页码：345 / 346
页数：2
相关论文
共 50 条
  • [31] Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database
    Iarikov D.
    Wassel R.
    Farley J.
    Nambiar S.
    Infectious Diseases and Therapy, 2015, 4 (4) : 433 - 458
  • [32] Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System
    Xue-feng Jiao
    Hai-long Li
    Xue-yan Jiao
    Yuan-chao Guo
    Chuan Zhang
    Chun-song Yang
    Li-nan Zeng
    Zhen-yan Bo
    Zhe Chen
    Hai-bo Song
    Ling-li Zhang
    Scientific Reports, 10
  • [33] Adverse Events Associated With Pediatric Use of Proton Pump Inhibitors: Analysis of the FDA Adverse Event Reporting System
    Alahmari, Abdullah K.
    Guo, Jeff J.
    Kelton, Christina Ml
    Wigle, Patricia R.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 236 - 236
  • [34] Adverse events of celecoxib associated with the central nervous system and cancer: a disproportionality analysis of the FDA adverse event reporting system
    Du, Yikuan
    Zhang, Mengting
    Chen, Mianhai
    Hu, Mianda
    Zeng, Wenqi
    Cai, Xiaolin
    Zhang, Weichui
    Zhu, Jinfeng
    Zhong, Mingjun
    Liu, Yi
    Yang, Chun
    EXPERT OPINION ON DRUG SAFETY, 2025,
  • [35] ADVERSE EVENTS ASSOCIATED WITH PEDIATRIC USE OF PROTON PUMP INHIBITORS: ANALYSIS OF THE FDA ADVERSE EVENT REPORTING SYSTEM
    Alahmari, A. K.
    Guo, J. J.
    Kelton, C. M.
    Wigle, P. R.
    VALUE IN HEALTH, 2013, 16 (03) : A211 - A211
  • [36] Adverse Events Associated with Colchicine Drug Interactions: Analysis of the Public Version of the FDA Adverse Event Reporting System
    Almalki, Ziyad S.
    Guo, Jeff J.
    Kelton, Christina M. L.
    Wigle, Patricia R.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 83 - 84
  • [37] Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System
    Jiao, Xue-feng
    Li, Hai-long
    Jiao, Xue-yan
    Guo, Yuan-chao
    Zhang, Chuan
    Yang, Chun-song
    Zeng, Li-nan
    Bo, Zhen-yan
    Chen, Zhe
    Song, Hai-bo
    Zhang, Ling-li
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [38] Comprehensive evaluation of leuprorelin-associated adverse events: insights from FDA adverse event reporting system
    Tang, Xiao
    Zheng, Fuchun
    Ma, Zifang
    Shen, Huilong
    Yao, Zhijun
    EXPERT OPINION ON DRUG SAFETY, 2025, 24 (03) : 355 - 364
  • [39] Pharmacovigilance Analysis Of FDA Adverse Event Reporting System (FAERS) Events For Inclisiran
    Rajak, Kripa
    Halder, Anupam
    Gautam, Seema Sharma
    Khanal, Resha
    Atrash, Anas
    Goswami, Rohan
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2023, 43
  • [40] A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor
    Pan, Yunyan
    Wang, Yu
    Zheng, Yifan
    Chen, Jie
    Li, Jia
    FRONTIERS IN PHARMACOLOGY, 2024, 15
12345